Nuo Xu

Nuo Xu

Auto-generated profile, based on publicly available information

Nuo Xu

Shanghai Cancer Institute 1 State Key Laboratory of Systems Medicine for Cancer Department of Liver Surgery Shanghai Jiao Tong University School of Medicine, Shanghai, China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2026 in Cancer Discovery
Verified
Journal Article
Closed access
CYChen Yang
Chen Yang
NXNuo Xu
Nuo Xu
SJShuyi Ji
Shuyi Ji
XCXifu Cheng
Xifu Cheng
QLQian Li
Qian Li
CWCun Wang
Cun Wang
Adenosquamous carcinoma (ASC) in intrahepatic cholangiocarcinoma (iCCA) has long been considered rare (∼1 to 2%), yet its occurrence portends lethal disease progression. In this study, we identify latent squamous plasticity, a transcriptionally primed yet histology-silent state that is quantifiable by a squamous transition potential (STP) index. Approximately 20% to 30% of patients with iCCA can be classified as STP high and experience ASC-like dismal outcomes. Mechanistically, FOS-like 1 (FOSL1) acts as a plasticity trigger, driving a temporally ordered squamous program by reshaping the chromatin landscape. Additionally, it cooperates with p63 in an enhancer-dependent manner to dysregulate PTGS2/COX-2 expression. The resulting intratumoral prostaglandin (PG) E2 accumulation drives neutrophil-mediated FOXP3-negative type I regulatory T-cell (Tr1) polarization and predisposes STP-high tumors to immunotherapy resistance. Through a drug-repurposing screen, we identify celecoxib as a dual-function agent that counteracts latent squamous plasticity while fostering an immunopermissive state, providing a clinically actionable strategy for squamous-biased iCCA now being evaluated in a phase Ib/II trial (NCT07632235). Significance: Latent squamous plasticity defines a common yet histologically occult high-risk state in iCCA, driven by FOSL1-dependent enhancer reprogramming and coupled to a PGE2-dependent neutrophil–Tr1 immunosuppressive circuit. By integrating STP-based stratification with celecoxib repurposing, this study identifies latent squamous plasticity as a clinically actionable vulnerability to improve iCCA treatment responsiveness.